Latest
11
Nov
From Ivory Tower to Wall Street: Monetizing University Biotech Royalties
A scientist in a university lab toils over a breakthrough therapy. Years later, that discovery becomes a best-selling drug, delivering
28 min read
10
Nov
Navigating Regulatory and Reimbursement Disruption: How Accelerated Approvals and Pricing Reforms Are Reshaping Pharmaceutical Royalty Valuations
Introduction: The Perfect Storm of Regulatory and Pricing Uncertainty
The pharmaceutical royalty market is experiencing an unprecedented convergence of regulatory
44 min read
09
Nov
The Weekly Term Sheet (45)
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
45 min read
08
Nov
The Return of Royalty
On 19 November, as the Jefferies London Healthcare Conference closes for the day, a different conversation begins. Registration for our
5 min read
07
Nov
Fund of the Week: Lilly Ventures – Eli Lilly's Strategic Biotech Investor
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
20 min read
06
Nov
Company of the week: Hemab Therapeutics
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
22 min read
05
Nov
Multiple Royalty Streams on a Single Drug: Practical Realities
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
18 min read
04
Nov
Royalty Stream Sales and Buybacks in Pharma Financing
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
12 min read
03
Nov
China's Venture Capital Landscape in 2025 – Slump and Retreat
China's biotech venture capital (VC) sector in 2025 is recovering from a deep slump. After peaking at $15.
10 min read
02
Nov
The Weekly Term Sheet (44)
Disclaimer: This article is for informational purposes only and does not constitute legal, financial, or investment advice. The author is
27 min read